SELECT PUBLICATIONS

Coiffier B et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235-42. Abstract

Kaminski MS et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352(5):441-9. Abstract

Kewalramani T et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103(10):3684-8. Abstract

Pfreundschuh MG et al. Randomized Intergroup trial of first line treatment for patients ≤ 60 years with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) with a CHOPlike regimen with or without the anti-CD20 antibody rituximab — Early stopping after the first interim analysis. Presentation. ASCO 2004a;Abstract 6500.

Pfreundschuh MG et al. First analysis of the completed Mabthera International (MInT) Trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): Addition of rituximab to a CHOP-like regimen significantly improves outcomes of all patients with the identification of a very favorable subgroup with IPI=0 and no bulky disease. Presentation. ASH 2004b;Abstract 157.

Pfreundschuh M et al; German High-Grade Non-Hodgkin’s Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 2004c;104(3):626-33. Abstract

Pfreundschuh M et al; German High-Grade Non-Hodgkin’s Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004d;104(3):634-41. Abstract